Cart
sales@molnova.com
Tyrphostin A25
CAS No. 118409-58-8
Tyrphostin A25( —— )
Catalog No. M33749 CAS No. 118409-58-8
Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.3 μM for GPR35.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 49 | Get Quote |
|
| 10MG | 71 | Get Quote |
|
| 25MG | 113 | Get Quote |
|
| 50MG | 167 | Get Quote |
|
| 100MG | 242 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTyrphostin A25
-
NoteResearch use only, not for human use.
-
Brief DescriptionTyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.3 μM for GPR35.
-
DescriptionTyrphostin 25 (AG82) is a specific inhibitor of the EGFR tyrosine kinase. Tyrphostin 25 is also a GPR35 agonist with an IC50 of 0.94 μM and an EC50 of 5.3 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR | GPR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number118409-58-8
-
Formula Weight202.17
-
Molecular FormulaC10H6N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=C(C#N)C#N)C1=CC(O)=C(O)C(O)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Klemke RL, et al. Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol. 1994 Nov;127(3):859-66. ?
molnova catalog
related products
-
ZD-4190
ZD-4190 is a inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling used for the treatment of cancer.
-
Lifirafenib
Lifirafenib is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.
-
EMI1
EMI1 can be used in the mutant EGFR-associated, drug-resistant non-small-cell lung cancer(NSCLC) research. EMI1 is an inhibitor of EGFR L858R/T790M/C797S and EGFR ex19del/T790M/C797S .
